Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders

Series A proceeds fund advancement of the company's lead program through clinical proof-of-concept study in atopic dermatitis and progression of broader precision I&I pipeline